SPRC:NASDAQSciSparc Ltd. Analysis

SciSparc Ltd. (SPRC) is trading at $4.98, well below its 20‑day and 50‑day SMAs (~$7.02) and far beneath the DCF‑derived fair value of $26.52, suggesting a massive valuation gap. The stock sits just above the calculated support of $4.53 and below the resistance at $11.45, with a bearish MACD, an RSI of 37 and a steep 30‑day volatility of nearly 290%, indicating short‑term downside pressure despite increasing volume.
Fundamentally, the company is distressed: revenue of $0.86 M has fallen 34.5%, operating margin is –8.5%, and cash flow is negative, while cash on hand (~$4.6 M) barely covers modest debt ($0.37 M) leading to a debt‑to‑equity of 7.1. The biotech sector’s high regulatory and execution risk is amplified by the recent conditional approval for NeuroThera Labs’ acquisition of CliniQuantum, a move that could broaden the pipeline but adds execution uncertainty. The market’s “Extreme Greed” sentiment (FGI 89) may be driving the recent price rally, yet the underlying financial health remains weak.